The Effect of Polyethylene Glycol on Constipation Prophylaxis After Benign Gynecological Laparoscopy: A Randomized Controlled Trial.

OBJECTIVE

To evaluate whether the short-term postoperative use of polyethylene glycol (PEG) 3350 can reduce the rate of constipation following benign gynecological laparoscopy.

DESIGN

Double-blind randomized placebo-controlled trial

SETTING

A tertiary teaching hospital in Melbourne, Australia.

PATIENTS: Patients on the surgical waitlist undergoing an elective benign gynecological laparoscopy, aged 18-60 years, and English speaking.

INTERVENTIONS: Patients were randomized to a single daily dose (17g) of PEG 3350, or placebo (maltodextrin) for 7 days postoperatively MEASUREMENTS: The primary outcome was the rate of constipation in the week following surgery defined using a modified ROME IV criteria. Secondary outcomes included bowel habit symptoms, constipation rates, time to first bowel motion, postoperative pain and distress levels, laxative and opiate use, adverse side effects and unplanned medical review for bowel habits. These were measured at 1 and 6 weeks after surgery.

MAIN

RESULTS

A total number of 115 patients were randomized, with 89 included in the final analysis: Forty-eight in the control group and 41 in the intervention group. Baseline characteristics and preoperative bowel habit were similar between groups. Postoperative constipation at 1 week was 51% in the intervention group and 71% in the control group reflecting a 20% absolute risk reduction with a risk ratio of 0.72 (95% CI 0.51-1.03, p = .08). Specific constipation symptoms were significantly lower in the intervention group including straining (39% vs 62%), lumpy/hard stools (29% vs 56%), and sensation of anorectal blockage (29% vs 56%) (all p <.05). No serious adverse events occurred and mild side effects were infrequent and similar across groups.

CONCLUSION

Short-term use of PEG 3350 following benign gynecological laparoscopy did not significantly reduce overall constipation rates at 1 week, but was well tolerated and associated with improvements in specific constipation symptoms.

CLINICAL TRIAL REGISTRATION: The trial was prospectively registered with the Australian New Zealand Clinical trial registry at ANZCTR.org.au (ACTRN12623000330640) on 29/03/2023. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385526&isReview=true.